Cargando…

Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity

The expression of high mobility group box 1 (HMGB1), breast cancer susceptibility gene 1 (BRCA1) and P62 in ovarian cancer was investigated to explore its association with chemotherapy sensitivity in ovarian cancer patients. Tumor tissues and para-carcinoma normal tissues of 60 ovarian cancer patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shouyong, Wei, Yanlei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958823/ https://www.ncbi.nlm.nih.gov/pubmed/29844838 http://dx.doi.org/10.3892/ol.2018.8482

Ejemplares similares

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer
por: Iwadate, Reiko, et al.
Publicado: (2014)

Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas
por: Langer, Rupert, et al.
Publicado: (2018)

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2018)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)

Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours
por: Wiggins, George A. R., et al.
Publicado: (2020)

Nuclear Fructose‐1,6‐Bisphosphate Inhibits Tumor Growth and Sensitizes Chemotherapy by Targeting HMGB1
por: Li, Yeyi, et al.
Publicado: (2023)

NAC1 Modulates Sensitivity of Ovarian Cancer Cells to Cisplatin via Altering the HMGB1-Mediated Autophagic Response
por: Zhang, Yi, et al.
Publicado: (2011)

BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis
por: Salwa, Amreen, et al.
Publicado: (2021)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

BRCA1 promoter hypermethylation in sporadic epithelial ovarian carcinoma: Association with low expression of BRCA1, improved survival and co-expression of DNA methyltransferases
por: BAI, XUEFENG, et al.
Publicado: (2014)

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations
por: Wang-Gohrke, S, et al.
Publicado: (1999)

Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy
por: Sekiguchi, Fumiko, et al.
Publicado: (2020)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions
por: Wang, Yiying, et al.
Publicado: (2017)

Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2019)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells
por: Horiuchi, Akiko, et al.
Publicado: (2007)

Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA‐negative breast cancers
por: Xu, Ye, et al.
Publicado: (2017)

Poly (ADP-ribosylation) of HMGB1 facilitates its acetylation and promotes HMGB1 translocation-associated chemotherapy-induced autophagy in leukaemia cells
por: Li, Yunyao, et al.
Publicado: (2020)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response
por: Cámara-Quílez, María, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

Bicyclol Alleviates Signs of BDL-Induced Cholestasis by Regulating Bile Acids and Autophagy-Mediated HMGB1/p62/Nrf2 Pathway
por: Zhao, Jingwen, et al.
Publicado: (2021)

Prognostic relevance of autophagy-related markers p62, LC3, and Beclin1 in ovarian cancer
por: Jovanović, Ljubiša, et al.
Publicado: (2022)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer
por: Yan, Xiao-Yu, et al.
Publicado: (2020)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_uo2i1d9g1o6avifbrohr0g3cs1